pocare-platform-img-3 (1)

Initial success for Orgenesis’ POCare Platform

Pharmaceutical companies used to be eager buyers of technology. But in recent years, biotech platforms have benefited from easier access to capital as independent entities, eliminating the need to sell. At the same time, biopharma companies large and small are realizing that building a platform is better than focusing on a single product or production[…]

Imcyse

Imcyse signs licensing agreement with Pfizer

Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]

TOP 20 Belgian Biotech Companies 2021

TOP 20 Belgian Biotech Companies 2021

Belgium and its companies at the forefront of the biotechnology industry in Europe Belgium is spearheading the European biotech industry. Meet some of the most successful cases of Belgian biotechnology companies. Belgium is one of the countries that provide the most to the biotech industry in Europe, as it has a total of more than[…]

delphi_genetics

Catalent acquires Delphi Genetics for $55M

Catalent Pharma takes over Delphi Genetics. The Gosselies BioPark will be its European Center of Excellence in Gene and Cell Therapy. Delphi Genetics is one of ULB‘s oldest spin-offs, created twenty years ago. The company, which employs around 40 people, is a pharmaceutical subcontracting company (CDMO) specializing in cell and gene therapies. Its mission is not to develop treatments,[…]

DSC_1875-copie-scaled2

Novadip receives 9.4 M€ of non-dilutive funding

The Walloon Region Government to support the development of treatments at Novadip with 9.4M€ of non-dilutive funding Novadip Biosciences, a clinical-stage company developing treatments to regenerate damaged tissues in patients with significant unmet medical needs, has announced that the US Food and Drug Administration (FDA) has granted the designation of Rare Pediatric Disease and Orphan[…]

1600335902672

OUAT! raises 500k€ with the Innovation Fund

  OUAT! recently raised 500k€ with the Innovation Fund. The capital infusion will support the further development of HakoBio and the roll out of the software to new clients. OUAT! aims to facilitate the digital transformation of the life sciences industry. In increasingly intelligent and connected factories, OUAT! enables the men and women of the biopharmaceutical industry to achieve[…]

1608194538472-square-2

Univercells raises €70 million in Series C Financing

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. Univercells recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed,[…]

George Soros

Univercells, beneficiary of financial support from major investors

Many large investors have already set their sights on the Walloon company Univercells. Among them stands out the American billionaire George Soros; famous financier and philanthropist at the age of 90, Adjuvant Capital; a fund linked to the Bill Gates galaxy, the federal government through SFPI, and the Walloon government through SRIW. Bill Gates, as[…]

Screenshot 2020-10-31 at 02.41.00

Greenomy is the International Laureate of the Fintech for Tomorrow Challenge 2020

Greenomy, the first regtech SaaS platform enabling companies and investors to comply with the new EU Sustainable Finance Taxonomy Regulation, has been selected as the International Laureate of the Fintech for Tomorrow Challenge 2020. This award acknowledges their ambition as technological facilitators to the implementation of the EU Taxonomy Regulation. By helping companies and investors to[…]

0 (2)

Savics is nominated for the Prize D4D 2020

Savics has been nominated for the Prize D4D (Digital for Development) 2020. This ceremony organized by the Royal Museum for Central Africa (RMCA) rewards outstanding initiatives that significantly contribute to the digital development in the South. These initiatives exploit the potential of (new) technologies in order to contribute to the Sustainable Development Goals (SDG’s) set by the United Nations. DataToCare was recognized in[…]

tibia_actu2_def copy

World first: a child’s tibia healed thanks to a 3D bone graft from Novadip technology

  This is a world first in the field of orthopaedic surgery: surgeons at Cliniques universitaires de Saint-Luc repaired the tibia bone of a 5-year-old child using a bone graft implant, a technology developed by the UCLouvain spin-off Novadip Biosciences. The child had congenital nonunion of the tibia, a rare and disabling disease. He was[…]

univercells_bill_gates

Bill Gates invests in Univercells again

    Univercells has just completed a new funding round of around 50 million €. Among its investors, a fund linked to the Bill & Melinda Gates Foundation, which has already helped the Walloon biotech on several occasions. The list of investors includes Adjuvant Global Health Technology Fund, a fund originally linked to the Bill & Melinda Gates[…]

sanofi_pasteur_digital_twins

Sanofi Pasteur uses HakoBio, the Digital Twins platform developed by OUAT!

Sanofi Pasteur has used digital twin technologies and Virtual Reality through HakoBio to design their new Evolutive Vaccine Facility. HakoBio online platform is developed by our customer OUAT! The reasons why Sanofi Pasteur has accelerated the design of its Evolutive Vaccine Facility using digital twins are: Sanofi Pasteur used digital twin technologies through HakoBio to model its new facility and democratize[…]

ouat_webinar

Rewatch the webinar about Digital Twins hosted by OUAT! and Pall Biotech

How digital twins facilitate access to the factory of tomorrow Webinar / 19.06.2020 Discover through a real-life case study how Pall Biotech is using the 3D digital twin to simplify conceptual design of new facilities, accelerate decisions and reduce errors. You can directly access the webinar HERE or read a short summary below first. Smart applications have made[…]

digital_orthopaedics_ceo

Digital Orthopaedics is looking for its new CEO

Digital Orthopaedics is an innovative e-Health company providing a comprehensive Clinical Decision Support System (CDSS) for musculoskeletal pathologies, for the foot and ankle in particular. Digital Orthopaedics’ ambition is to transform the planning and execution of orthopedic surgeries and treatment with the ultimate goal of personalizing orthopedic treatments through the innovative use of ideation, modeling and 3D[…]

digital_orthopaedics_ankle_foot

Digital Orthopaedics introduced their new platform 3DOXpert

June was a busy month for Digital Orthopaedics. During a webinar co-organized with Synopsys, the company’s engineers described how they generate patient-specific digital twins; a mechanical replica of the patient’s foot, using image & motion analysis. This event was followed by Simbio-M, another virtual conference focused on new technologies in the field of biomechanics and[…]

novadip_3M3_platform

Novadip unveiled its 3M³ Platform at BIO Digital 2020

Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Novadip Biosciences, a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it will unveil details of its 3M3 miRNA delivery platform in a recorded presentation at the BIO Digital conference, which is took place[…]

bonehealing

Novadip progresses in bone healing treatment

Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]

pdcline_bfmbusiness

PDC*line Pharma on BMF Business

Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html